1.Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy for diffuse large B-cell lymphoma in pregnancy may be associated with preterm birth.
Eun Ju LEE ; Ki Hoon AHN ; Soon Cheol HONG ; Eun Hee LEE ; Yong PARK ; Byung Soo KIM
Obstetrics & Gynecology Science 2014;57(6):526-529
Lymphoma, especially non-Hodgkin's lymphoma is extremely rare in pregnancy. A 24-year-old pregnant woman was diagnosed with diffuse large B-cell lymphoma (DLBCL), a subgroup of non-Hodgkin's lymphoma, at 24 weeks' gestation, and was treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy. After 4 cycles of R-CHOP, she delivered a healthy baby via cesarean section at 34 weeks and 5 days' gestation because of preterm contraction-related fetal distress. The patient was administered the remaining 2 cycles of R-CHOP after delivery. Follow-up magnetic resonance imaging and computed tomography showed complete remission. Here, we report a rare case of DLBCL successfully treated with R-CHOP chemotherapy during pregnancy, we also performed a systematic review of literature for similar cases. There were 3 earlier reports of R-CHOP treatment for DLBCL. All cases, including our case, resulted in preterm birth. Together, these findings suggest that R-CHOP chemotherapy for DLBCL in pregnancy may be associated with preterm birth.
Cesarean Section
;
Cyclophosphamide*
;
Doxorubicin*
;
Drug Therapy*
;
Female
;
Fetal Distress
;
Follow-Up Studies
;
Humans
;
Lymphoma
;
Lymphoma, B-Cell*
;
Lymphoma, Non-Hodgkin
;
Magnetic Resonance Imaging
;
Prednisone*
;
Pregnancy*
;
Pregnant Women
;
Premature Birth*
;
Vincristine*
;
Young Adult
;
Rituximab
2.The effect of maternal HBV DNA levels on HBV intrauterine transmission and fetal distress.
Jing WANG ; Tao Tao YAN ; Ya Li FENG ; Ying Li HE ; Yuan YANG ; Jin Feng LIU ; Nai Juan YAO ; Ya Ge ZHU ; Ying Ren ZHAO ; Tian Yan CHEN
Chinese Journal of Hepatology 2022;30(8):873-878
Aim: To identify the key risk factors of intrauterine hepatitis B virus transmission (HBV) and its effect on the placenta and fetus. Methods: 425 infants born to hepatitis B surface antigen (HBsAg)-positive pregnant women who received combined immunization with hepatitis B immunoglobulin and hepatitis B vaccine between 2009 to 2015 were prospectively enrolled in this study. The intrauterine transmission situation was assessed by dynamic monitoring of infants HBV DNA load and quantitative HBsAg. Univariate and multivariate regression analysis was used to determine the high risk factors for intrauterine transmission. Stratified analysis was used to determine the relationship between maternal HBV DNA load and fetal distress. Transmission electron microscopy was used to observe HBV Effects on placental tissue. Results: HBV intrauterine infection rate was 2.6% (11/425). Multivariate analysis result showed that the maternal HBV DNA load was an independent risk factor for intrauterine infection among infants (P=0.011). Intrauterine infection and distress rate was significantly higher in infants with with maternal HBV DNA>106 IU/ml than those with HBV DNA <106 IU/ml (12.2% vs. 1.8%; χ2=11.275, P=0.006), and (24.4% vs. 16.0%, χ2=3.993, P=0.046). Transmission electron microscopy showed that mitochondrial edema, endoplasmic reticulum expansion and thicker basement membrane were apparent when the maternal HBV DNA>106 IU/ml than that of maternal HBV DNA<106 IU/ml (960 nm vs. 214 nm, Z=-2.782, P=0.005) in the placental tissue. Conclusion: Maternal HBV DNA>106 IU/ml is associated not only with intrauterine infection, but also with increased incidence of intrauterine distress and placental sub-microstructural changes, providing strong clinical and histological evidence for pregnancy avoidance and treatment in this population.
DNA, Viral
;
Female
;
Fetal Distress/drug therapy*
;
Hepatitis B/prevention & control*
;
Hepatitis B Surface Antigens
;
Hepatitis B Vaccines/therapeutic use*
;
Hepatitis B virus/genetics*
;
Humans
;
Immunoglobulins/therapeutic use*
;
Infant
;
Infectious Disease Transmission, Vertical/prevention & control*
;
Placenta
;
Pregnancy
;
Pregnancy Complications, Infectious
3.A case of acute lymphocytic leukemia in pregnancy.
Hyun Jung CHOI ; Yong Won PARK ; June Won CHEONG ; You Hong MIN ; Ja Yong KWON ; Han Sung KWON ; Young Han KIM ; Sung Hoon KIM
Korean Journal of Obstetrics and Gynecology 2005;48(2):467-472
The incidence of acute leukemia in pregnancy is estimated to be about 1 per 75000 pregnancies, and the incidence of lymphocytic leukemia is known to be lower than myelocytic leukemia. Pregnancy dose not affect the course of acute leukemia, but thrombocytopenia, anemia and leukopenia resulting from leukemia may lead to hemorrhage, infection, and insufficient supply of oxygen and nutrition to fetus. The most important factor for chemotherapy is gestational age. Since no evidence on adverse effect of chemotherapeutic agents on fetus when given after the first trimester, aggressive chemotherapy is recommended during pregnancy. However, during chemotherapy, caution regarding risk of spontaneous abortion, intrauterine fetal growth retardation, teratogenicity, intrauterine fetal death, fetal immunosupression and preterm labor should be taken. Acute leukemia in pregnancy is extremely rare, so treatment and management of the pregnant mother bearing viable fetus in her 3rd trimester is not established clearly. We experienced a patient with acute lymphocytic leukemia who was first diagnosed at 27 gestational weeks and immediately started with chemotherapy. But due to preterm labor and impending fetal distress, emergency cesarean section was performed at 28 gestational weeks. We present this patient along with past experiences of acute leukemia in pregnancy.
Abortion, Spontaneous
;
Anemia
;
Cesarean Section
;
Drug Therapy
;
Emergencies
;
Female
;
Fetal Death
;
Fetal Distress
;
Fetal Growth Retardation
;
Fetus
;
Gestational Age
;
Hemorrhage
;
Humans
;
Incidence
;
Leukemia
;
Leukemia, Lymphoid
;
Leukemia, Myeloid
;
Leukopenia
;
Mothers
;
Obstetric Labor, Premature
;
Oxygen
;
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
;
Pregnancy Trimester, First
;
Pregnancy*
;
Thrombocytopenia
4.Effect of Antenatal Corticosteroid and Antibiotics in Pregnancies Complicated by Premature Rupture of Membranes between 24 and 28 weeks of Gestation.
Journal of Korean Medical Science 2005;20(1):88-92
The aim of this study was to assess the effectiveness of active intervention with antenatal maternal corticosteroid and antibiotics therapy in infants delivered between 24 and 28 weeks of gestation after premature rupture of membrane. This retrospective study included pregnant women complicated by preterm delivery at the Dong-A University Hospital from 1998 to 2002. Patients were divided into labor induction group 1 (n=20), observation group 2 (n=19), and medication group 3 (n=20). We evaluated the effects of prolongation of pregnancy and intervention with maternal corticosteroids and antibiotics therapy on perinatal and neonatal outcomes. Each group did not have a significant difference (p<0.05) in neonatal outcomes, such as respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, retinopathy of prematurity, pneumonia, bronchopulmonary dysplasia, and sepsis. The mean latency period was 4.7 days and 7.6 days in groups 2 and 3, respectively. Therefore, this study was unable to demonstrate any beneficial effects of corticosteroids in improving neonatal outcomes and prolongation of the latency period with antibiotics.
Adrenal Cortex Hormones/*pharmacology
;
Adult
;
Anti-Bacterial Agents/*pharmacology
;
Apgar Score
;
Female
;
Fetal Membranes, Premature Rupture/*drug therapy
;
Gestational Age
;
Humans
;
Infant, Newborn
;
Maternal Age
;
Pregnancy
;
Pregnancy Outcome
;
Pregnancy Trimester, Second
;
Premature Birth/prevention & control
;
Respiratory Distress Syndrome, Newborn/prevention & control
;
Retrospective Studies
;
Time Factors